Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin and metformin for weight loss in obesity class III
NCT03968224Phase 3Completed
- Sponsor
- Unidad Médica de Alta Especialidad Centro Médico Nacional Siglo XXI
- Start
- Aug 2018
- Primary completion
- Jul 2024
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dapagliflozin in type 2 diabetes mellitus (T2DM) and prediabetes, sponsored by Unidad Médica de Alta Especialidad Centro Médico Nacional Siglo XXI. Primary endpoint: Change in Body Weight at 12 months. Started Aug 2018; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)prediabetes
Beyond the preview
Go deeper on NCT03968224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03968224.